Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of Autolus Therapeutics plc from 30 Sep 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Autolus Therapeutics plc quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 30 Sep 2015 to 30 Sep 2025.
  • Autolus Therapeutics plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 30 Sep 2025 was $87,622,000, a 87% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

Autolus Therapeutics plc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $87,622,000 -$570,915,000 -87% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $125,332,000 -$581,627,000 -82% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $97,251,000 -$662,293,000 -87% 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $228,804,000 -$11,531,000 -4.8% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $658,537,000 +$401,688,000 +156% 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $706,959,000 +$399,127,000 +130% 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $759,544,000 +$416,189,000 +121% 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $240,335,000 -$142,426,000 -37% 31 Dec 2023 10-Q 12 Nov 2025 2025 Q3
Q3 2023 $256,849,000 +$93,481,000 +57% 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $307,832,000 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $343,355,000 31 Mar 2023 10-Q 17 May 2024 2024 Q1
Q4 2022 $382,761,000 +$72,085,000 +23% 31 Dec 2022 10-K 20 Mar 2025 2024 FY
Q3 2022 $163,368,000 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q4 2021 $310,676,000 +$156,591,000 +102% 31 Dec 2021 10-K 21 Mar 2024 2023 FY
Q1 2021 $239,798,000 -$4,300,000 -1.8% 31 Mar 2021 6-K 06 May 2021 2021 Q1
Q4 2020 $154,085,000 -$57,345,000 -27% 31 Dec 2020 10-K 21 Mar 2024 2023 FY
Q3 2020 $178,481,000 -$51,566,000 -22% 30 Sep 2020 6-K 05 Nov 2020 2020 Q3
Q2 2020 $212,830,000 -$54,047,000 -20% 30 Jun 2020 6-K 06 Aug 2020 2020 Q2
Q1 2020 $244,098,000 +$55,684,000 +30% 31 Mar 2020 6-K 06 May 2021 2021 Q1
Q4 2019 $211,430,000 -$6,125,000 -2.8% 31 Dec 2019 20-F 07 Mar 2023 2022 FY
Q3 2019 $230,047,000 -$17,042,000 -6.9% 30 Sep 2019 6-K 05 Nov 2020 2020 Q3
Q2 2019 $266,877,000 +$1,961,000 +0.74% 30 Jun 2019 6-K 06 Aug 2020 2020 Q2
Q1 2019 $188,414,000 31 Mar 2019 6-K 07 May 2020 2020 Q1
Q4 2018 $217,555,000 +$88,571,000 +69% 31 Dec 2018 20-F 10 Mar 2022 2021 FY
Q3 2018 $247,089,000 +$110,019,000 +80% 30 Sep 2018 20-F 04 Mar 2021 2020 FY
Q2 2018 $264,916,000 30 Jun 2018 6-K 08 Aug 2019 2019 Q2
Q4 2017 $128,984,000 31 Dec 2017 6-K 07 Nov 2019 2019 Q3
Q3 2017 $137,070,000 +$109,011,000 +389% 30 Sep 2017 20-F 04 Mar 2021 2020 FY
Q3 2016 $28,059,000 +$17,856,000 +175% 30 Sep 2016 20-F 03 Mar 2020 2019 FY
Q3 2015 $10,203,000 30 Sep 2015 20-F 25 Feb 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.